Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination
Objective: We aimed to determine the relationship between vaccine-related adverse effects and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) in Japan. Methods: We enrolled 378 healthcare workers (255 wo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/3/451 |
| _version_ | 1797441133262929920 |
|---|---|
| author | Ryousuke Koike Michiru Sawahata Yosikazu Nakamura Yushi Nomura Otohiro Katsube Koichi Hagiwara Seiji Niho Norihiro Masuda Takaaki Tanaka Kumiya Sugiyama |
| author_facet | Ryousuke Koike Michiru Sawahata Yosikazu Nakamura Yushi Nomura Otohiro Katsube Koichi Hagiwara Seiji Niho Norihiro Masuda Takaaki Tanaka Kumiya Sugiyama |
| author_sort | Ryousuke Koike |
| collection | DOAJ |
| description | Objective: We aimed to determine the relationship between vaccine-related adverse effects and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) in Japan. Methods: We enrolled 378 healthcare workers (255 women and 123 men) whose Ab titers were analyzed 3 and 6 months after the second dose in our previous study and whose characteristics and adverse effects were collected previously by using a structured self-report questionnaire. Results: The workers’ median age was 44 years. Although injection-site symptoms occurred with almost equal frequency between the first and second doses, systemic adverse effects, such as general fatigue and fever, were significantly more frequent after the second dose than after the first dose. Multivariate analysis showed that fever was significantly correlated with female participants for the second dose (odds ratio (OR), 2.139; 95% confidence interval (95% CI), 1.185–3.859), older age for the first dose (OR, 0.962; 95% CI, 0.931–0.994) and second dose (OR, 0.957; 95% CI, 0.936–0.979), and dyslipidemia for the first dose (OR, 8.750; 95% CI, 1.814–42.20). Age-adjusted Ab titers at 3 months after vaccination were 23.7% and 23.4% higher in patients with a fever than in those without a fever after the first and second dose, respectively. In addition, age-adjusted Ab titers at 3 and 6 months after the second dose were, respectively, 21.7% and 19.3% higher in the group in which an anti-inflammatory agent was used than in the group without the use of an anti-inflammatory agent. Conclusion: Participants with systemic adverse effects tend to have higher Ab titers from 3 to 6 months after the second dose of the BNT162b2 vaccine. Our results may encourage vaccination, even among people with vaccine hesitancy related to relatively common systemic adverse effects. |
| first_indexed | 2024-03-09T12:18:35Z |
| format | Article |
| id | doaj.art-242e2e59177e43dab8c416a5bd621a5c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:18:35Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-242e2e59177e43dab8c416a5bd621a5c2023-11-30T22:43:07ZengMDPI AGVaccines2076-393X2022-03-0110345110.3390/vaccines10030451Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after VaccinationRyousuke Koike0Michiru Sawahata1Yosikazu Nakamura2Yushi Nomura3Otohiro Katsube4Koichi Hagiwara5Seiji Niho6Norihiro Masuda7Takaaki Tanaka8Kumiya Sugiyama9Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDepartment of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDepartment of Public Health, Jichi Medical University, Shimotsuke 329-0498, JapanDepartment of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDepartment of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDivision of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke 329-0498, JapanDepartment of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu 321-0293, JapanDepartment of Surgery, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDepartment of Orthopaedic Surgery, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanDepartment of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital, Utsunomiya 329-1193, JapanObjective: We aimed to determine the relationship between vaccine-related adverse effects and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine (Pfizer/BioNTech) in Japan. Methods: We enrolled 378 healthcare workers (255 women and 123 men) whose Ab titers were analyzed 3 and 6 months after the second dose in our previous study and whose characteristics and adverse effects were collected previously by using a structured self-report questionnaire. Results: The workers’ median age was 44 years. Although injection-site symptoms occurred with almost equal frequency between the first and second doses, systemic adverse effects, such as general fatigue and fever, were significantly more frequent after the second dose than after the first dose. Multivariate analysis showed that fever was significantly correlated with female participants for the second dose (odds ratio (OR), 2.139; 95% confidence interval (95% CI), 1.185–3.859), older age for the first dose (OR, 0.962; 95% CI, 0.931–0.994) and second dose (OR, 0.957; 95% CI, 0.936–0.979), and dyslipidemia for the first dose (OR, 8.750; 95% CI, 1.814–42.20). Age-adjusted Ab titers at 3 months after vaccination were 23.7% and 23.4% higher in patients with a fever than in those without a fever after the first and second dose, respectively. In addition, age-adjusted Ab titers at 3 and 6 months after the second dose were, respectively, 21.7% and 19.3% higher in the group in which an anti-inflammatory agent was used than in the group without the use of an anti-inflammatory agent. Conclusion: Participants with systemic adverse effects tend to have higher Ab titers from 3 to 6 months after the second dose of the BNT162b2 vaccine. Our results may encourage vaccination, even among people with vaccine hesitancy related to relatively common systemic adverse effects.https://www.mdpi.com/2076-393X/10/3/451SARS-CoV-2viral infectionclinical epidemiologyadverse effect |
| spellingShingle | Ryousuke Koike Michiru Sawahata Yosikazu Nakamura Yushi Nomura Otohiro Katsube Koichi Hagiwara Seiji Niho Norihiro Masuda Takaaki Tanaka Kumiya Sugiyama Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination Vaccines SARS-CoV-2 viral infection clinical epidemiology adverse effect |
| title | Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination |
| title_full | Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination |
| title_fullStr | Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination |
| title_full_unstemmed | Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination |
| title_short | Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination |
| title_sort | systemic adverse effects induced by the bnt162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination |
| topic | SARS-CoV-2 viral infection clinical epidemiology adverse effect |
| url | https://www.mdpi.com/2076-393X/10/3/451 |
| work_keys_str_mv | AT ryousukekoike systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT michirusawahata systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT yosikazunakamura systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT yushinomura systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT otohirokatsube systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT koichihagiwara systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT seijiniho systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT norihiromasuda systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT takaakitanaka systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination AT kumiyasugiyama systemicadverseeffectsinducedbythebnt162b2vaccineareassociatedwithhigherantibodytitersfrom3to6monthsaftervaccination |